1) Swerdlow SH, et al : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2008.
日本臨牀 73/増刊8 リンパ腫学
目次
- 日本臨牀 73/増刊8 リンパ腫学
―目次―
特集 リンパ腫学 最新の研究動向
?．総 論
1 病理診断の変遷と展望
2 画像診断の変遷と展望--FDG-PET/CTを中心に--
3 化学療法と分子標的療法の変遷と展望
4 放射線療法の変遷と展望
5 造血幹細胞移植の変遷と展望
II．リンパ腫の疫学と危険因子
1 日本のリンパ腫疫学的動向と諸外国との比較
2 HTLV-1感染の疫学と病原性発現機構
3 リンパ腫の危険因子
III．リンパ組織の生物学とリンパ腫の発症機序
1 リンパ組織の形態と機能
2 リンパ球の分化とリンパ腫発症機構
3 リンパ腫発症の分子生物学的機序
4 自己免疫疾患とリンパ腫発症
5 慢性炎症とリンパ腫発症
6 リンパ腫におけるマクロファージの役割
IV．リンパ腫研究の動向
1 B細胞リンパ腫
2 T細胞リンパ腫
3 Hodgkinリンパ腫
4 悪性リンパ腫モデル細胞の作成と
その薬剤スクリーニングへの応用
5 APOBEC3Bによる新規リンパ腫発症機構
V．リンパ腫に関するガイドライン概説
−日本血液学会造血器腫瘍診療ガイドラインについて−
VI．リンパ腫のWHO分類(2008)
1 WHO分類第4版(2008)の概説と病型頻度
2 前駆型リンパ球系腫瘍
3 成熟B細胞腫瘍
4 成熟性T細胞およびNK細胞腫瘍
5 Hodgkinリンパ腫(全6項目)
6 免疫不全関連リンパ増殖異常症
7 組織球および樹状細胞腫瘍(全8項目)
VII．リンパ腫の検査・診断
1 リンパ腫の検査・診断：概論
2 臨床症状からの診断と他疾患ならびに
反応性リンパ節腫大との鑑別
3 画像診断
4 リンパ節生検
5 病期診断規準
VIII．リンパ腫の予後予測因子
1 悪性リンパ腫の予後指標
2 ホジキンリンパ腫の予後因子
3 グラスゴー指数
4 生物学的予後因子(表面抗原、遺伝子変異など)
IX．リンパ腫の治療
1 総 論
2 各 論
X．節外リンパ腫の臓器別特徴と治療
1 中枢神経系原発悪性リンパ腫
2 骨リンパ腫
3 皮膚リンパ腫と皮下脂肪織炎様T細胞リンパ腫
4 原発性滲出性リンパ腫 (PEL)
5 眼・眼付属器リンパ腫
6 鼻・副鼻腔リンパ腫
7 甲状腺リンパ腫
8 唾液腺リンパ腫
9 乳腺リンパ腫
10 肺リンパ腫・リンパ腫様肉芽腫症・膿胸関連リンパ腫
11 肝脾T細胞リンパ腫
12 消化管リンパ腫
13 副腎リンパ腫
14 精巣リンパ腫
15 子宮・卵巣リンパ腫
XI．特 論
1 キャッスルマン病
2 TAFRO症候群
3 IgG4関連疾患
4 Double-hit lymphoma
5 B細胞腫瘍に対するCAR T細胞療法
この書籍の参考文献
参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。
本参考文献は電子書籍掲載内容を元にしております。
I 総論
P.12 掲載の参考文献
P.20 掲載の参考文献
4) Schoder H, et al : Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgk in's lymphoma. J Clin Oncol 23 : 4643-4651, 2005.
13) Zinzani PL, et al : Early interim 18F-FDG PET in Hodgkin's lymphoma : evaluation on 304 patients, Eur J Nucl Med Mol Imaging 39 : 4-12, 2012.
14) Dupuis J, et al : Impact of [(18) F] fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy : a prospectivestudy from the Groupe d'Etudes des Lymphomes de l Adulte and GOELAMS. J Clin Oncol 30 : 4317-4322, 2012.
15) Esfahani SA, et al : Baseline total lesion glycolysis measured with (18) F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma : a pilot study. Am J Nucl Med Mol Imaging 3 : 272-281, 2013.
16) 長町茂樹ほか : 悪性腫瘍治療効果診断におけるFDG指標の有用性, 問題点について. 臨床放射線 59 : 1805-1811, 2014.
P.26 掲載の参考文献
14) Gopal AK, et al : PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370 (11) : 1008-1018, 2014.
P.33 掲載の参考文献
6) Yahalom J : Patients with H pylori-independent MALT lymphoma are curable with radiotherapy. Oncology 25 (12) : 1147-1149, 2011.
P.40 掲載の参考文献
5) 張高明ほか : 中等度悪性非ホジキンリンパ腫に対する自己末梢血幹細胞移植併用大量化学療法-臨床前期第II相試験-. 臨床血液 40 : 1058-1067, 1999.
9) Nowakowski GS, et al : Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma : a phase II study. J Clin Oncol 33 : 251-257, 2015.
13) Ansell SM, et al : PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 : 311-319, 2014.
II リンパ腫の疫学と危険因子
P.48 掲載の参考文献
2) Olson JH : Epidemiology. In : Textbook of Malignant Haematology (ed by Degos L, et al), p 1-22, CRC Press, London, 1999.
7) Lymphoma Study Group of Japanese Pathogenesis : The World Health Organization classification of malignant lymphomas in Japan : Incidence of recently recognized entities. Pathol Int 50 : 696-702, 2000.
8) Aclinical evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma. Blood 89 : 3909-3918, 1997.
11) Ko YH, et al : REAL classification of malignant lymphomas in the Republic of Korea : incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 83 : 806-812, 1998.
12) National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas : summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project, Cancer 49 : 2112-2135, 1982.
13) Harris NL, et al : Arevised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Study Group. Blood 84 : 1361-1392, 1994.
P.53 掲載の参考文献
7) Satou Y, et al : HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog 7 : e1001274, 2011.
P.58 掲載の参考文献
1) Chan JKC, et al : Extranodal NK/T-cell lymphoma, nasal type. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Sreven SH, et al), p 285-288, Lyon, IARC, 2008.
2) Chan JKC, et al : Aggressive NK-cell leukemia. In : World Health Organization Classification of Tumors : Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, p 276-277, Lyon, IARC Press, 2008.
9) Rickinson AB, Kieff E : Epstein-Barr Virus, In : Fields Virology (ed by Knipe DM, Howley P), p2604-2699, Lippincott Williams & Wilkins Press, 2013.
10) 新井文子 : 臨床血液 56 : 269-277, 2015.
13) Nakamura M, et al : Elevated expression of activation-induced cytidine deaminase in T and NK cells from patients with chronic active Epstein-Barr virus infection. Eur J Dermatol 21 : 780-782, 2011.
P.63 掲載の参考文献
2) Damania BA, Cesearman E : Kaposi's sarcoma-associated herpeg. virus. In : Fields Virology, Vol. 2 (ed by Knipe DM, Howley PM), p 2080-2128, Lippincott Williams & Wilkins, Philadelphia, 2013.
5) Purushothaman P, et al : Transcriptome analysis of Kaposi's sarcoma-associated herpesvirus during de novo primary infection of human B and endothelial cells. J Virol 89 : 3093-3111, 2015.
11) Aoki Y, et al : Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93 : 4034-4043, 1999.
13) Burger R, et al : Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 91 : 1858-1863, 1998.
P.69 掲載の参考文献
2) de Sanjose S, et al : Hepatitis C and non-Hodgkin Iymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol 6 : 451-458, 2008.
7) Zuckeman E, et al : The effect of antiviral therapy on t (14 ; 18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 97 : 1555-1559, 2001.
P.73 掲載の参考文献
4) Raphael M, et al : Lymphomas associated with HIV infection. In : WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH), p 340-342, WHO press, 2008.
P.78 掲載の参考文献
1) Isaacson PG, et al : Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed (ed by Swerdlow SH, et al), p 214-217, IARC Press, Lyon, 2008.
2) Nakamura S, Matsumoto T : Helicobacter pylo夕i and gastric mucosa-associated lymphoid tissue lymphoma : recent progress in pathogenesis and management. World J Gastroenterol 19 : 8181-8187, 2013.
8) Du MQ : MALT lymphoma : many roads lead to nuclear factor-κB activation. Histopathology 58 : 26-38, 2011.
11) Lin WC, et al : Translocation of Helicobacter pylori CagA into human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res 70 : 5740-5748, 2010.
P.84 掲載の参考文献
1) Shugart YY, et al : Apparent anticipation and heterogeneous transmission patterns in familial Hodgkin's and non-Hodgkin's lymphoma : report from a study based on Swedish cancer database. Leuk Lymphoma 42 : 407-4152001.
4) Morio T : Common variable immunodeficiency : the spectrum of disease manifestations and molecular basis of the disorder. Rinsho Ketsueki 54 : 1983-1991, 2013.
13) Cerhan JR, et al : Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet 46 : 1233-1238, 2014.
P.90 掲載の参考文献
1) 独立行政法人放射線医学総合研究所監訳 : 放射線の線源と影響. 原子放射線の影響に関する国連科学委員会UNSCEAR 2008年報告書第2巻, p 158-171, 独立行政法人放射線医学総合研究所, 2013.
5) 青山喬, 丹羽太貫 (編著) : 放射線基礎医学第12版, p 169 -220, 金芳堂, 2013.
6) 江島洋介, 木村博 (共編), 日本放射線技術学会 (監修) : 放射線生物学, p72-76, オーム社, 2008.
III リンパ組織の生物学とリンパ腫の発症機序
P.100 掲載の参考文献
1) 内山安男, 相磯貞和 (監訳) : Ross組織学, p 396-441, 南江堂, 2010.
2) 松島綱治, 山田幸宏 (監訳) : Abbas, Lichtman, Pillai分子細胞免疫学, 第7版, p 267-319, Elsevier, 2014.
3) Ioachim's lymph node pathology, 4th ed (ed by Ioachim HL Medeiros LJ), Wolters Kluwer/Lippincott Williams & Wlkins, p 2-14, 2008.
6) 清野宏 (編) : 臨床粘膜免疫学. p124-177, シナジー, 2010.
P.104 掲載の参考文献
2) Muramatsu M, et al : Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102 : 553-563, 2000.
12) Swerdlow SH CE, et al (eds) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, Lyon, 2008.
P.111 掲載の参考文献
11) Akasaka H, et al : Molecular anatomy of BCL6 translocations revealed by Iong-distance polymerase chain reaction-based assays. Cancer Res 60 : 2335-2341, 2000.
15) Ansell SM, et al : PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 : 311-319, 2015.
P.115 掲載の参考文献
1) Afshar-Sterle S. et al : Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat Med 20 : 283-290, 2014.
14) Treon SP, et al : MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 367 : 826-833. 2012.
P.121 掲載の参考文献
30) Lee JH, et al : nm23-H1 protein expression and gene mutation in 150 patients with non-Hodgkin's lymphomas, J Korean Med Sci 21 (4) : 645-651, 2006.
35) Feldman AL, et al : Discovery of recurrent t (6 ; 7) (p25. 3 ; q32. 3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 117 (3) : 915-919, 2011.
40) Jager R, et al : Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. Anticancer Res 25 (5) : 3191-3196, 2005.
42) Turner SD, et al : CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. Anticancer Res 26 (5A) : 3275-3279, 2006.
P.127 掲載の参考文献
9) Tobon GJ, et al : Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 65 : 3218-3227, 2013.
P.133 掲載の参考文献
1) WHO classification of tumours of haematopoietic and lymphoid tissues (ed by Swerdlow SH, et al), IARC, Lyon, 2008.
13) Hasui K, et al : Quantitative highly-sensitive immunohistochemistry (Modified ImmunoMax) of HTLV-1 p40tax and p27rex proteins in HTLV-1-associated non-neoplastic lymphadenopathy (HANNLA) with estimation of HTLV-1 dose by polymerase chain reaction. Dendritic Cells 7 : 19-27, 1997.
14) Takenouchi N, et al : Molecular pathologic analysis of the tonsil in HTLV-1-infected individuals. J Acquir Immune Defic Syndr 22 : 200-207, 1999.
15) Hara H, et al : Clustering of CARMA1 through SH3-GUK domain interactions is required for its activation of NF-κB signaling. Nat Commun 6 : 5555, 2015.
P.139 掲載の参考文献
6) 菰原義弘, 竹屋元裕 : がん間質におけるマクロファージ : 腫瘍随伴マクロファージ (TAM)の役割とそのマーカー. 病理と臨床 32 : 17-23, 2014.
10) Steidl C, et al : Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362 : 875-885, 2010.
11) 菰原義弘ほか : ATLLにおけるCD163陽性マクロファージの重要性 (The clinical significance of CD163-positive tumor associated macrophages in ATLL). 血液内科 68 : 36-68, 2014.
IV リンパ腫研究の動向
P.147 掲載の参考文献
3) Kobayashi S, et al : Identification of IGHCδ-BACH2 fusion transcripts resulting from cryptic chromosomal rearrangements of 14q32 with 6q15 in aggressive B-cell lymphoma/leukemia. Genes Chromosomes Cancer 50 : 207-216, 2011.
4) Kurata M, et al : Characterization of t (3 ; 6) (q27 ; p21) breakpoints in B-cell non-Hodgkin's lymphoma and construction of the histone H4/BCL6 fusion gene, leading to altered expression of Bcl-6. Cancer Res 62 (21) : 6224-6230, 2002.
6) Hosokawa Y, et al : The Ikaros gene, a central regulator of lymphoid differentiation, fuses to the BCL6 gene as a result of t (3 ; 7) (q27 ; p12) translocation in a patient with diffuse large B-cell lymphoma. Blood 95 (8) : 2719-2721, 2000.
8) Hummel M, et al : A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354 (23) : 2419-2430, 2006.
P.153 掲載の参考文献
1) 土橋映仁 : 次世代シークエンサーとリンパ腫. 病理と臨床 33 : 512-516, 2015.
7) Morin R, et al : Somatic mutations altering EZH 2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42 (2) : 181-185, 2010.
10) Treon SP, et al : MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 367 (9) : 826-833, 2012.
P.157 掲載の参考文献
6) Stein H, et al : Diffuse large B-cell lymphoma, not otherwise specified, p 233-237, IARC Press, Lyon, 2008.
9) Marcucci F, et al : The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma-a review. Am J Blood Res 2 : 18-28, 2012.
13) 岩切大ほか : EBウイルスによる発癌機構.ウイルス 56 : 201-208, 2006.
P.162 掲載の参考文献
1) Swerdlow SH, et al : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, Lyon, 2008.
2) Nakamura M, et al : Frequent alterations of the p14 (ARF) and p16 (INK4a) genes in primary central nervous system lymphomas. Cancer Res 61 : 6335-6339, 2001.
8) Xu X, et al : Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC : report of two cases and literature review. Int J Clin Exp Pathol 6 (4) : 788-794, 2013.
P.166 掲載の参考文献
3) Nepomuceno RR, et al : Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 63 : 4472-4480, 2003.
15) Sapra P, Allen TM : Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 62 : 7190-7194, 2002.
P.171 掲載の参考文献
3) Satou Y, et al : HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog 7 : e1001274, 2011.
4) Kamada N, et al : Chromosome abnormalities in adult T-cell leukemia/lymphoma : a karyotype review committee report. Cancer Res 52 : 1481-1493, 1992.
12) Zhao T, et al : HTLV-1 bZIP factor enhances TGF-β signaling through p300 coactivator. Blood 118 : 1865-1876, 2011.
P.175 掲載の参考文献
9) Yamaglshi M, et al : Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell 21 : 121-135, 2012.
P.181 掲載の参考文献
2) Miyatake Y, et al : Anchorage-dependent multicellular aggregate formation induces CD44 high cancer stem cell-like ATL cells in an NF-κB-and vimentin-dependent manner. Cancer Lett 357 : 355-363, 2015.
P.185 掲載の参考文献
2) Treon SP, et al : MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 367 : 826-833, 2012.
P.189 掲載の参考文献
P.194 掲載の参考文献
1) Bargou RC, et al : High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87 (10) : 4340-4347, 1996.
5) 田丸淳一 : リンパ腫の検査・診断 診断 ホジキンリンパ腫の病理診断. 日本臨牀 72 (3) : 450-455. 2014.
8) Martin-Subero JI, et al : Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 99 (4) : 1474-1477, 2002.
13) Tokunaga F, et al : Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation. EMBO J 31 (19) : 3856-3870, 2012.
P.200 掲載の参考文献
4) Sugimoto K et al : Drug development targeting microenvironment for malignant lymphoma. ASH Annual Meeting Abstracts 120 : Abstract 1661, 2012.
P.203 掲載の参考文献
3) Muramatsu M, et al : Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102 : 553-563, 2000.
V リンパ腫に関するガイドライン概説 - 日本血液学会造血器腫瘍診療ガイドラインについて -
P.215 掲載の参考文献
1) 日本血液学会 (編) : 造血器腫瘍診療ガイドライン2013年版, 金原出版, 2013.
2) 日本血液学会, 日本リンパ網内系学会 (編) : 造血器腫瘍取扱い規約, 金原出版, 2010.
VI リンパ腫のWHO分類 ( 2008 )
P.225 掲載の参考文献
1) Jaffe ES. et al : Introduction and overview of the classification of the lymphoid neoplasms. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p158-166, International Agency for Research on Cancer (IARC), Lyon, 2008.
3) Treon SP, et al : MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 367 : 826-833, 2012.
P.229 掲載の参考文献
1) Swerdlow SH, et al : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. LARC, Lyon, 2008.
4) Borowitz MJ, et al : Acute leukemia of ambiguous lineage. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p 150-155, IARC, Lyon, 2008.
5) Harris NL, et al : A revised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Study Group. Blood 84 : 1361-1392, 1994.
6) Jaffe ES, et al : Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001.
7) Borowitz MJ, Chan JKC : Blymphoblastic leukaemia/lymphoma, not otherwise specified. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p168-170, IARC, Lyon, 2008.
11) Raimondi SC, et al : Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia 10 : 213-224, 1996.
17) Foon KA, et al : Immunologic classification of acute lymphoblastic leukemia. Implications for normal lymphoid differentiation. Blood 56 (6) : 1120-1126, 1980.
18) Coustan-Smith E, et al : Early T-cell precursor leukaemia : a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10 (2) : 147-156, 2009.
P.246 掲載の参考文献
1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC press, 2008.
2) 直江知樹ほか (編) : WHO血液腫瘍分類-WHO分類2008をうまく活用するために-, 医薬ジャーナ社, 2010.
12) Traverse-Glehen A, et al : Splenic diffuse red pulp small-B cell lymphoma : toward the emergence of a new lymphoma entity. Discov Med 13 : 253-265, 2012.
13) Machii T, et al : Predominance of a distinct subtype of hairy cell leukemia in Japan. Leukemia 7 : 181-186, 1993.
14) Treon SP, et al : MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 367 : 826-833, 2012.
19) Taddesse-Heath L, et al : Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol 27 : 522-531, 2003.
20) 中峯寛和ほか : Hodgkinリンパ腫および濾胞性リンパ腫の発生頻度の推移について. 日病理会誌 91 : 346, 2002.
30) 日本皮膚悪性腫瘍学会, 皮膚がん予後統計委員会 : 皮膚リンパ腫全国症例数調査2013第30回日本皮膚悪性腫瘍学会学術大会.
40) Dave SS, et al : Molecular diagnosisof Burkitt's lymphoma. N Engl J Med 354 : 2431-2442, 2006.
P.257 掲載の参考文献
1) Sreven SH, et al : World Health Organization Classification of Tumors : Tumors of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC) Press, Lyon, 2008.
3) The Non-Hodgkin's Lymphoma Classification Project : A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89 : 3909-3918, 1997.
P.264 掲載の参考文献
2) Swerdlow SH, et al (eds) : World Health Organization classification of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon, 2008.
3) 田丸淳一 : わが国のホジキンリンパ腫の特徴と他疾患との鑑別ポイント. 血液内科 64 (3) : 227-232, 2012.
4) Prakash S, et al : IgD positive L & H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol 30 (5) : 585-592, 2006.
9) Stein H, et al : The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue : evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66 (4) : 848-858, 1985.
10) Tamaru J, et al : Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood 49 (8) : 752 -758, 1994.
11) Kueppers R, et al : Cellular origin of human B-cell lymphomas. N Engl J Med 341 : 1520, 1999.
12) Marafioti T, et al : Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 95 (4) : 1443-1450, 2000.
14) Bargou RC, et al : Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100 : 2961, 1997.
P.269 掲載の参考文献
1) Swerdlow SH, et al : WHO Classification of Tumors : Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2008.
5) Elenitoba-Johnson KS, Jaffe ES : Lymphoproliferative disorders associated with congenital immunodeficiencies. Semin Diagn Pathol 14 : 35-47, 1997.
10) Camilleri-Broet S, et al : AIDS-related primary brain lymphomas : histopathologic and immunohistochemical study of 51 cases. Hum Pathol 28 : 367-374, 1997.
12) Landgen O, et al : Risk factors for lymphoproliferative disorders after allogenic hematopoietic cell transplantation. Blood 113 : 4992-5001, 2009.
19) Hoshida Y, et al : Lymphoproliferative disorders in rheumatoid arthritis : clinicopathologic analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34 : 322-331, 2007.
26) Nakamura S, et al : EBV-positive diffuse large B-cell lymphoma. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p 243-244, Lyon, France, IA, RC, 2008.
P.276 掲載の参考文献
5) O'Malley DP, et al : The genetics of interdigitating dendritic cell sarcoma share some changes with Langerhans cell histiocytosis in select cases. Ann Diagn Pathol 18 : 18-20, 2014.
6) Ge R, et al : Clinicopathologic characteristics of inflammatory pseudotumor-like follicular dendritic cell sarcoma. Int J Clin Exp Pathol 7 : 2421-2429, 2014.
8) Narvaez-Moreno B, et al : Disseminated juvenile xanthogranuloma associated with follicular lymphoma in an adult : successful treatment with chemotherapy and rituximab. A review of the literature. Actas Dermosifiliogr 104 : 242-246, 2013.
VII リンパ腫の検査・診断
P.284 掲載の参考文献
1) Swerdlow SH, et al : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC, Lyon, 2008.
3) 日本血液学会, 日本リンパ網内系学会 (編) : 造血器腫瘍取扱い規約, 第1版, 金原出版, 2010.
4) Harris NL, et al : A revised European-American classification of lymphoid neoplasm : A proposal from the International Lymphoma Study Group. Blood 84 : 1361-1392, 1994.
5) 押味和夫 : カラーテキスト血液病学, 第1版, 中外医学社, 2007.
6) Carbone PP, et al : Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31 : 1860-1861, 1971.
11) Cheson BD, et al : Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17 : 1244-1253, 1999.
P.289 掲載の参考文献
4) Fijten GH, Blijham GH : Unexplained lymphadenopathy in family practice. An evaluation of the probability of malignant causes and the effectiveness of physicians' workup. J Fam Pract 27 : 373-376, 1988.
8) Pangalis GA, et al : Clinical approach to lymphadenopathy. Semin Oncol 20 : 570-582, 1993.
P.295 掲載の参考文献
1) Cheson BD, et al : Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 : 1244-1253, 1999,
5) 寺内隆司 : 非ホジキンリンパ腫のresponse criteriaとCTによる治療効果判定. 内科 90 : 432-436, 2002.
P.300 掲載の参考文献
1) http://www.jcpet.jp/1-3-4-1日本核医学会PET核医学分科会HOMEページ.
3) Juweid ME, et al : Use of positron emission tomography for response assessment of lymphoma : Consensus recommendations of the lmaging Subcommittee of the lnternational Harmonization Project in Lymphoma. J Clin Oncol 25 : 571-578, 2007.
8) Pakos EE, et al : 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma : A meta -analysis. J Nucl Med 46 : 958-963, 2005.
14) Itti E, et al : An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma : comparison between Deauville criteria and ΔSUVmax. Eur J Nucl Med Mol Imaging 40 : 1312-1320, 2013.
15) Dupuis J, et al : Impact of [(18) F] fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy : a prospective study from the Groupe d'Etudesdes Lymphomes de l'Adulte and GOELAMS. J Clin Oncol 30 : 4317-4322, 2012.
P.305 掲載の参考文献
1) Banks PM : Technical factors in the preparation and evaluation of lymph node biopsies. In : Neoplastic Hematopathology. 2nd ed (ed by Knowles DM), p 467 -482, Lippincott Williams and Wilkins. Philadelphia, 2001.
2) Rosai J : Lymph node evaluation. In : Rosai and Ackerman's Surgical Pathology, 10th ed, p 1773-1780, Mosby, St Louis, 2011.
3) Ioachim HL Medeiros LJ : Ioachim's Lymph Node Pathology, Lippincott Williams & Wilkins, p 16-20, Philadelphia, 2009.
4) O'Malley DP, et al : Technical evaluation and overview of lymph node and spleen. In : Atlas of Nontumor Pathology, Benign and Reactive Conditions of Lymph Node and Spleen, p 57-74, 2009.
5) 大島孝一 : リンパ節ならびに節外臓器の取り扱い方. リンパ腫アトラス, p38-41, 文光堂, 2014.
P.310 掲載の参考文献
1) Weiss LM : Lymph Nodes, p ix, Cambridge University Press, New York, 2008.
2) Ioachim HL, Medeiros LI : Ioachim's Lymph Node Pathology, Lippincott Williams & Wilkins, Wolters Kluwer, 2009.
3) Hematopathology (ed by Jaffe ES, et al), Elsevier Saunders, 2011.
4) Knowles' Neoplastic Hematopathology (ed by Orazi A, et al), Lippincott Williams & Wilkins, Wolters Kluwer, 2014.
5) リンパ腫アトラス, 第4版 (大島孝一ほか編), 文光堂, 2014.
6) 中峯寛和ほか : 病理診断. 悪性リンパ腫のすべて. 血液・腫瘍科49巻補冊, p286-295, 科学評論社, 2004,
7) 中峯寛和 : 病理診断 (免疫染色も). みんなに役立つ悪性リンパ腫の基礎と臨床, 改訂版 (押味和夫編), p119-126. 医薬ジャーナル社, 2011.
8) Bowowits MJ, et al : Acute leukaemias of ambiguous lineage. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p 150-155, IARC, 2008.
11) O'Malley DP, et al : Practical applications in immunohistochemistry. Evaluation of diffuse large B-cell lymphoma and related large B-cell Lymphomas. Arch Pathol Lab Med 139 : 1094-1107, 2015.
12) 中峯寛和 : 悪性リンパ腫の病理診断学. 奈良医誌 59 : 135-148, 2008.
P.316 掲載の参考文献
1) 蒲貞行ほか : リンパ節スタンプ標本による反応性病変と悪性リンパ腫の細胞学的鑑別について. 日本検査血液学会雑誌 5 : 380-390, 2004.
2) 所嘉朗 : 悪性リンパ腫の細胞診. 臨床病理 58 : 1113-1120, 2010.
3) 青木定夫 : CLLの形態観察における乾燥法の違いについて. 日本検査血液学会雑誌 15 : 396-403, 2014.
4) 矢野美由紀ほか : 多項目自動血球分析装置XE-5000による体腔液測定の検討. 日本検査血液学会雑誌 11 : 308-315, 2010.
5) 栗田宗次 : リンパ節の構造と構成細胞, 悪性リンパ腫細胞診アトラス (栗田宗次ほか編), p8-12, 名古屋大学出版会, 名古屋, 1994.
6) 西国広 : リンパ節スタンプ標本の見方. 日本検査血液学会雑誌 5 : 391-399, 2004.
7) 押味和夫 : NK細胞の異常増殖. NK細胞基礎から臨床へ (押味和夫), p 125-142, 金原出版, 1993.
8) 森茂郎 : 悪性リンパ腫の病理診断-その学術的および社会的課題について-. リンパ腫アトラス改訂・改題第4版 (森茂郎監修, 大島孝一ほか編), p49-56, 文光堂, 2014.
11) 濱川真治 : セルブロック法. 顕微鏡検査ハンドブック臨床に役立つ形態学 (菅野治重ほか編), p274-277, 医学書院, 2012.
13) Nakamura S, et al : Intravascular large B-cell lymphoma. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p 252-253, IARC, Lyon, 2008.
14) Dogan A, et al : Angioimmunoblastic T-cell lymphoma. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p 309-311, IARC, Lyon, 2008.
P.324 掲載の参考文献
1) 米山彰子 : 表面形質. 三輪血液病学第3版 (浅野茂隆監), p567-580, 文光堂, 2006.
2) 米山彰子 : フローサイトメトリー. 三輪血液病学第3版 (浅野茂隆監), p1945-1954, 文光堂, 2006.
3) 米山彰子 : フローサイトメトリー解析. 血液内科クリニカルスタンダード (第2版) (東原正明ほか編), p49-52, 文光堂, 2008.
4) 米山彰子 : 細胞表面抗原. スタンダードフローサイトメトリー (日本サイトメトリー技術者認定協議会編), p55-79, 医歯薬出版, 2009.
P.330 掲載の参考文献
1) Shaffer LG, et al : ISCN (2013) : An International System for Human Cytogenetic Nomenclature (2013), Karger, 2013.
2) Heim S, Mitelman F : Cancer Cytogenetics. Wiley-Blackwell, 2009.
3) 三浦偉久男 : 染色体分析とその解釈, 臨床血液 48 : 1393-1399, 2007.
4) 三浦偉久男 : 造血器腫瘍における染色体転座, 臨床血液 49 : 318-324, 2008.
5) 三浦偉久男 : 血液悪性腫瘍の染色体異常-最新の知見-, 日内会誌 100 : 503-508, 2011.
P.338 掲載の参考文献
1) 谷脇雅史ほか : 血液腫瘍-MIC-M診断から治療まで-, p 97-113, 先端医学社, 2005.
2) 阿部達生ほか : 造血器腫瘍アトラス第4版, p86-101, 日本医事新報社, 2009.
3) 谷脇雅史ほか : 第37回組織細胞化学講習会 組織細胞化学2012, 日本組織細胞化学会, p85-100, 2012.
4) ISCN 2013 : An International System for Human Cytogenetic Nomenclature (2013) (ed by Lisa G. Shaffer, et al), Karger, Basel, 2013.
P.344 掲載の参考文献
4) 岡部實裕ほか : Ig遺伝子, TCR遺伝子の再構成解析法. 日本臨牀 47 (増刊号) : 485-491, 1989.
5) Yokota S, et al : Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77 : 331-339, 1991.
P.349 掲載の参考文献
2) Carbone PP, et al : Report of the committee on Hodgkin's disease staging classification. Cancer Res 31 : 1860-1861, 1971.
4) 日本血液学会, 日本リンパ網内系学会 (編) : 造血器腫瘍取扱い規約. 金原出版, 2010.
5) AJCC Cancer Staging Manual, 6th ed, p 393-403, Springer, New York, 2002.
9) TNM Classification of Malignant Tumours, 7th ed, p 304-310, Wiley-Backwell, Oxford, 2010.
VIII リンパ腫の予後予測因子
P.357 掲載の参考文献
9) Hasenclever D, Diehl V : A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339 (21) : 1506-1514, 1998.
P.362 掲載の参考文献
2) Carbone PP, et al : Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31 (11) : 1860-1861, 1971.
3) Mauch PM : Controversies in the management of early stage Hodgkin's disease. Blood 83 (2) : 318-329, 1994.
4) Tubiana M, et al : Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials : 1964-1987. Blood 73 (1) : 47-56, 1989.
5) Noordijk EM, et al : Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma : long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24 (19) : 3128-3135, 2006.
7) Meyer RM, et al : Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma : National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23 (21) : 4634-4642, 2005.
8) Hasenclever D, Diehl V : A prognostic score for advanced Hodgkin's disease. Intemational Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339 (21) : 1506-1514, 1998.
P.366 掲載の参考文献
11) Yang DH, et al : Weekly Four Times Rituximab Consolidation Following Reduced Cycles of R-CHOP lnduction Chemotherapy in Extremely Elderly Patients with Diffuse Large B Cell Lymphoma. Blood 122 (21) : 3031, 2013.
12) Kim Y, et al : The modified Glasgow Prognostic Scores as a predictor in diffuse Iarge B cell lymphoma treated with R-CHOP regimen. Yonsei Med J 55 : 1568-1575, 2014.
P.374 掲載の参考文献
9) Xu-Monette ZY, et al : Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP : report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 120 (19) : 3986-3996, 2012.
14) Nakamura N, et al : Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen. Eur J Haematol 91 (4) : 322-331, 2013.
15) Persky DO, et al : Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 97 (6) : 937-942, 2012.
IX リンパ腫の治療
P.382 掲載の参考文献
1) Tew KD, et al : Alkylating agents. In : Cancer Chemotherapy and Biotherapy, 3rd ed (ed by Chabner BA, Longo DL), p 373-414, Lippincott-Raven Publishers, Philadelphia, 2001.
6) Messmann RA, et al : Antifolates. In : Cancer Chemotherapy & Biotherapy (ed by Chabner BA et al), p 139-184, Lippincott-Raven Publishers, Philadelphia, 1996.
7) 上田孝典, 山内高弘 : 代謝拮抗薬, Cytarabineと類似化合物, プリン拮抗薬. 抗がん薬の臨床薬理 (相羽惠介編), p252-275, 南山堂, 2013.
8) Moudi M, et al : Vinca alkaloids. Int J Prev Med 4 (11) : 1231-1235, 2013.
9) 福島俊洋 : アントラサイクリン系薬剤 アントラキノン系薬剤. 造血器腫瘍における薬剤の使い方-合理的投与法と展望 (上田孝典編), p310-315, 医薬ジャーナル社, 1998.
P.387 掲載の参考文献
1) Goldie JH, Coldman AJ : A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63 (11-12) : 1727-1733, 1979.
P.391 掲載の参考文献
1) 照井康二 : 再発治療抵抗性びまん性大細胞型B細胞リンパ腫. 血液フロンティア 20 (2) : 163-169, 2010.
2) Coiffier B, et al : Long-term outcome of patients in the LNH-98. 5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients : a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116 (12) : 2040-2045, 2010.
4) Gisselbrecht C, et al : Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28 (27) : 4184-4190, 2010.
9) 鈴宮淳司ほか : FL初回再発時の治療選択としては何が勧められるか. 造血器腫瘍診療ガイドライン2013年版 (一般社団法人日本血液学会編), p152-153, 金原出版, 2013.
10) Mussetti A, et al : Lifting the mantle : Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Blood Rev : pii : S0268-960X (14) 00083-6. doi : 10.1016/j. blre. 2014. 10.001, 2014. [Epub ahead of print].
11) 石澤賢一 : 再発, 再燃悪性リンパ腫の救援化学療法 よくわかる悪性リンパ腫のすべて (飛内賢正編), p306-319, 永井書店, 2008.
P.400 掲載の参考文献
1) Boross P, Leusen JH : Mechanisms of action of CD20 antibodies. Am J Cancer Res 2 : 676-690, 2012.
3) Persky DO, et al : Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 97 : 937-942, 2012.
7) Hutas G : Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs 9 : 1206-1215, 2008.
9) Goldenberg DM : The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma : the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 39 : 195-201, 2001.
10) Diloseph JF, et al : Antibody-targeted chemotherapy with CMC-544 : a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103 : 1807-1814, 2004.
P.407 掲載の参考文献
P.412 掲載の参考文献
4) Tobinai K, et al : Japanese phase II study of 9°Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 100 : 158-164, 2009.
8) Scholz CW, et al : 90Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma : 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 31 : 308-313, 2013.
10) Illidge TM, et al : Fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma : an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J Clin Oncol 32 : 212-218, 2014.
11) Morschhause F, et al : 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma : updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J Clin Oncol 31 : 1977-1983, 2013.
P.417 掲載の参考文献
1) Ravandi F, et al : Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 27 (32) : 5425-5430, 2009.
11) Moskowitz CH, et al : Analysis of primary refractory Hodgkin lymphoma patients in a randomized, placebo-controlled study of Brentuximab vedotin consolidation after autologous stem cell transplant. ICML, abstract, 120, 2015.
12) Ansell SM, et al : PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (4) : 311-319, 2015.
15) Kreitman RI, et al : Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia. J Clin Oncol 33 : abstr 7079, 2015.
P.423 掲載の参考文献
5) Philip T, et al : High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316 (24) : 1493」498, 1987.
6) Gisselbrecht C, et al : Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28 (27) : 4184-4190, 2010.
7) d'Amore F, et al : Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma : NLG-T-01. J Clin Oncol 30 (25) : 3093-3099, 2012.
9) Federico M, et al : High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21 (12) : 2320-2325, 2003.
10) Yuen AR, et al : Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89 (3) : 814-822, 1997.
12) Sorror ML, et al : Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index : A CIBMT(R) Study. Biol Blood Marrow Transplant, 2015.
P.427 掲載の参考文献
3) Pifiana JL, et al : Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma : long-term follow-up from two prospective multicenter trials. Haematologica 95 : 1176-1182, 2010.
11) Gisselbrecht C, et al : Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28 : 4184-4190, 2010.
12) van Kampen RJ, et al : Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation : an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 29 : 1342-1348, 2011.
16) Fenske TS, et al : Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma : Analysis of transplantation timing and modality. J Clin Oncol 32 : 273-281, 2013.
21) Sarana B, et al : Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation : a retrospective study based on the time of HLA typing and donor availability. Blood 115 : 3671-3677, 2010.
P.433 掲載の参考文献
5) Treon SP, et al : Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med 372 : 1430-1440, 2015.
17) Souers AJ, et al : ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19 : 202-208, 2013.
20) Palanca-Wessels MC, et al : Final results of a phase I study of the anti-CD79b antibody-drug conjugate DCDS4501A (Polatuzumab vedotin) in relapsed or refractory B-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 122 : 4400, 2013.
21) Ansell SM, et al : PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 : 311-319, 2015.
P.439 掲載の参考文献
2) Schimpff SC : Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 80 : 13-20, 1986.
5) Smith TJ, et al : 2006 update of recommendations for the use of white blood cell growth factors ; an evidence-based clinical practice guideline. J Clin Oncol 24 : 3187-3205, 2006.
6) 日本臨床腫瘍学会 (編) : 発熱性好中球減少症 (FN) 診療ガイドライン, 南江堂, 2012.
8) Masaoka T : Evidence-based recommendations on antimicrobial use in febrile neutropenia in Japan. Int J Hematol 68 : S5-S6, 1998.
11) Averbuch D, et al : European guidelines for empiric antibacterial therapy for febrile neutropenic patients in the era of growing resistance : summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98 : 1826-1835, 2013.
P.445 掲載の参考文献
2) Antiemesis : NCCN Clinical Practice Guidelines in Oncology Verl, 2015 [http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf] (2015 ; April Access).
3) 日本がん治療学会 : がん診療ガイドライン 制吐剤療法ver1.2, 2014. [http://jsco-cpg.jp/item/29/index.html] (2015 ; April Access).
8) Hogan-Dann CM, et al : Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA 252 : 2862-2863, 1984.
9) 宇野真二ほか : Vincristine投与により急性軸索障害を呈したCharcot-Marie-Tooth病合併悪性リンパ腫. 臨床血液 40 : 414-419, 1999.
15) Wood AM : Rituximab : an innovative therapy for non-Hodgkin's lymphoma. Am J Health Syst Pharm 58 : 215-229, 2001.
P.449 掲載の参考文献
8) 井口雅史ほか : 胃悪性リンパ腫化学療法後の胃穿孔を大網充填閉鎖法にて救命しえた1例. 癌の臨床 44 (2) : 296-300, 1998.
P.454 掲載の参考文献
P.459 掲載の参考文献
5) Chen G, et al : Systemic Epstein-Barr virus positive T-cell lymphoproliferative disease of childhood with hemophagocytic syndrome. Int J Clin Exp Pathol7 (10) : 7110-7113, 2014.
7) Takahashi N, et al : Lymphoma-associated hemophagocytic syndrome in Japan. Rinsho Ketsueki 40 (7) : 542-549, 1999.
14) 高橋直人 : 血球貪食症候群. 血液・腫瘍科 49 (Suppl 4) : 497-501, 2004.
P.463 掲載の参考文献
8) Seymour JF, Gagel RF : Calcitriol : the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 82 (5) : 1383-1394, 1993.
P.468 掲載の参考文献
5) Kim SJ, et al : Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab : analysis from the Asia Lymphoma Study Group. Eur J Cancer 49 (16) : 3486-3496, 2013.
P.474 掲載の参考文献
2) 中川雅夫 : 本邦における播種性血管内血液凝固 (DIC) の発症頻度・原因疾患に関する調査報告. 厚生省特定疾患血液凝固異常症調査研究班 平成10年度研究報告書, p52-72, 1999.
4) 青木延雄, 長谷川淳 : DIC診断基準の「診断のための補助的検査成績, 所見」の項の改訂について. 厚生省特定疾患血液凝固異常症調査研究班 平成4年度業績報告集, p37-41, 1988.
7) Cesarman-Maus G, et al : Absence of tissue factor is characteristic of lymphoid malignancies of both T-and B-cell origin. Thromb Res 133 : 606-609, 2014.
P.480 掲載の参考文献
10) 滑川道人 : 中枢神経系における悪性リンパ腫 : Overview. BRAIN and NERVE 66 : 907-916, 2014.
14) Storch-Hagenlocher B, et al : Molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis. Ann Neurol 47 : 211-217, 2000.
17) Schulz H, et al : Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 89 : 753-754, 2004.
19) 三橋啓太ほか : A病院における血液がんに対する化学療法時の口内炎の発症頻度について. 第12回日本口腔ケア学会総会・学術大会抄録集 24, 2015.
20) Sonis ST : A biological approach to mucositis. J Support Oncol 2 : 21-32 ; discussion 35-36, 2004.
P.486 掲載の参考文献
6) Asai H, et al : Secondary malignancies after rituximab+CHOP therapy in the patients with diffuse large B-cell lymphoma, 第72回日本血液学会総会, 横浜市 (パシフィコ横浜), 2010.
P.491 掲載の参考文献
1) Muller HK et al : Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed (ed by Swerdlow SH, et al), p180-182, International Agency for Research on Cancer, Lyon, 2008.
2) 青木定夫 : 慢性リンパ性白血病. 臨床血液 55 : 213-222, 2014.
7) 青木定夫 : 慢性リンパ性白血病 : 診断と遺伝子変異. 臨床血液 55 : 1981-1988, 2014.
17) Brown JR, et al : Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 123 : 3390-3397, 2014.
P.497 掲載の参考文献
1) Raets EA, et al : Gene expression profiling reveals intrinsic differences betWeen T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer 47 : 130-140, 2006.
2) Borowitz MJ, Chan JKC : Blymphoblastic leukemia, not otherwise specified. B lymphoblastic leukemia with recurrent genetic abnormalities. T lymphoblastic leukemia. In : WHO Classification of Tumors of Haematopoietic and Lymphoid tissues (ed by Swerdlow SH, et al), p 168 -178, IARC Press, 2008.
3) The Non-Hodgldn's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 11 : 3909-3918, 1997.
5) 岡本昌隆 : 悪性リンパ腫の病型頻度 悪性リンパ腫・臨床と病理-WHO分類 (第4版) に基づいて- (吉野正ほか編著), p74-81, 先端医学社, 2009.
P.503 掲載の参考文献
1) WHO classification of tumours of haematopoietic and lymphoid tissues (ed by Swerdlow SH, et al), IARC Press, Lyon, 2008.
3) Lenz G, et al : Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359 (22) : 2313-2323, 2008.
12) Shipp MA, et al : International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas : report of the jury. J Clin Oncol 17 (1) : 423-429, 1999.
P.509 掲載の参考文献
1) Swerdlow SH, et al : WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th ed, IARC, Lyon, 2008.
3) Pileri SA, et al : Primary mediastinal B-cell lymphoma : high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB. 1, and PU. 1 in the absence of immunoglobulins. Am J Pathol 162 : 243-253, 2003.
4) Copie-Bergman C, et al : MAL expression in lymphoid cells : further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol 15 : 1172-1180, 2002.
11) Zinzani P, et al : Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis : a retrospective multinational study on 426 previously untreated patients. Haematologica 87 : 1258-1264, 2002.
P.513 掲載の参考文献
1) Nakamura S, et al : Intravascular large B-cell lymphoma. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), IARC Press, Lyon, 2008.
3) Matsue K, et al : Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma. Ann Hematol 90 : 417-421, 2011.
7) Shimada K, et al : Central nervous system involvement in intravascular large B-cell lymphoma : a retrospective analysis of 109 patients. Cancer Sci 101 : 1480-1486, 2010.
8) Nakazato T, et al : [Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-hyper-CVAD/R-MTX-Ara-C regimen]. Rinsho Ketsueki 51 : 148-152, 2010.
9) Sekiguchi Y, et al : Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-CHOP therapy and intrathecal administration : acase report and review of literature. Int J Clin Exp Pathol 7 : 3363-3369, 2014.
P.521 掲載の参考文献
1) Swerdlow SH, et al : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues IARC, Lyon, 2008.
2) Stein H, et al : CD30 (+) anaplastic large cell lymphoma : a review of its histopathologic, genetic, and clinical features. Blood 96 : 3681-3695, 2000.
3) Bai RY, et al : Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96 : 4319 -4327, 2000.
7) Feldman AL, et al : Discovery of recurrent t (6 ; 7) (p25.3 ; q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 117 : 915-919, 2011.
10) Suzuki R, et al : Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96 : 2993-3000, 2000.
13) Falini B, et al : ALK+ lymphoma : clinico-pathological findings and outcome. Blood 93 : 2697-2706, 1999.
16) NCCN Guidelines : NCCN Clinical Practice Guidelines in Oncology Non-Hodgkin's Lymphomas, 2015. Ver2. [http://www.nccn.org/professionals/physician_91s/pdf/nhl.pdf]
18) 菅谷誠ほか : 日本皮膚科学会ガイドライン : 皮膚リンパ腫診療ガイドライン2011年改訂版. 日皮会誌 122 : 1513-1531, 2012.
P.528 掲載の参考文献
3) 造血器腫瘍診療ガイドライン作成委員会 : 成人T細胞白血病・リンパ腫 (ATL). 造血器腫瘍診療ガイドライン2013年版 (日本血液学会編), p228-238, 金原出版, 2013.
5) Fukushima T, et al : Characterization of long term survivors and a predictive model for aggressive adult T-cell leukemia-1ymphoma (ATL) : An ancillary study by the Japan Clinical Oncology Group, JCOGO902A 53rd ASH Annual Meeting, 2011.
9) 皮膚悪性腫瘍診療ガイドライン作成委員会 : 第5章 : 3. 成人T細胞白血病・リンパ腫. 科学的根拠に基づく皮膚悪性腫瘍診療ガイドラインII : 成人T細胞白血病・リンパ腫 (ATL). p 84-93, 金原出版, 2010.
10) 石田高司ほか : 血液内科医・皮膚科医のための統合ATL診療ガイドライン解説書2014. 臨床血液 55 (11) : 2257-2261, 2014.
11) 石田高司ほか : 血液内科医・皮膚科医のための統合ATL診療ガイドライン解説書2014. 日皮会誌 124 (12) : 2275-2279, 2014.
P.532 掲載の参考文献
1) Dogan A, et al : Angioimmunoblastic T-cell lymphoma. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p 309-311, IARC Press, Lyon, 2008.
4) Sakata-Yanagimoto M : Multistep tumorigenesis in peripheral T cell lymphoma. Int J Hematol published online 28 Jan 2015.
16) d'Amore F, et al : Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma : NLG-T-01. J Clin Oncol 30 : 3093-3099, 2012.
19) Zelenetz AD, et al : Non-Hodgkins lymphomas. NCCN clinical practice guidelines in Oncology(R), version 2, 2015.
P.537 掲載の参考文献
2) Lee J, et al : Extranodal natural killer T-cell lymphoma, nasal-type : aprognostic model from a retrospective multicenter study. J Clin Oncol 24 : 612-618, 2006.
5) 日本血液学会 (編) : 造血器腫瘍診療ガイドライン2013年版, 金原出版, 2013.
P.542 掲載の参考文献
2) Engert A, et al : Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363 : 640-652, 2010.
7) Younes A, et al : Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30 : 2183-2189, 2012.
8) Ansell SM, et al : PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 : 311-319, 2015.
P.553 掲載の参考文献
2) Fisher RI, et al : A clinical analysis of two indolent lymphoma entities : mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories) : a Southwest Oncology Group study. Blood 85 : 1075-1082, 1995.
4) The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89 : 3909-3918, 1997.
5) Yatabe Y, et al : Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma : a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 95 : 2253-2261, 2000.
7) Rosenbluth BD, Yahalom J : Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT). Int J Radiation Oncology Biol Phys 65 : 1185-1191, 2008.
16) Ogura M, et al : Phase II study of rituximab plus high-dose Ara-C (HADC) -containing chemotherapy (CTX) followed by ASCT in untreated mantle cell lymphoma (MCL) : Japan Clinical Oncology Group Study (JCOG0406). ASCO Meeting Abstracts May 31, 2015 : 8565.
20) O'Connor OA, et al : Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23 : 676-684, 2005.
22) Fisher RI, et al : Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. J Clin Oncol 24 : 4867-4874, 2006.
24) Ogura M, et al : Efficacy and Safety of Bortezomib Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in Japanese Patients (Pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL) Not Considered for Transplantation Enrolled in the International, Randomized, Phase 3 LYML3002 Study (NCT00722137). Blood 124 : 3061 (abstract), 2014.
38) Tobinai K, et al : Japanese Phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 100 : 158-164, 2009.
39) Wang M, et al : Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. Clin Oncol 27 : 5213-5218, 2009.
P.560 掲載の参考文献
5) Bartlett NL, et al : Ibrutinib monotherapy in relapsed/refractory follicular lymphoma (FL) : preliminary results of a phase 2 consortium (P2C) trial. Blood 124 : Abstract 800, 2014.
7) Flinn I, et al : A phase 1 evaluation of duvelisib (IPI-145), a PI3K-δ,γ inhibitor, in patients with relapsed/refractory iNHL. Blood 124 : Abstract 802, 2014.
12) Kimby E, et al : Rituximab plus lenalidomide improves the complete remission rate in comparison with rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. Primary endpoint analysis of the randomized phase-2 trial SAKK 35/10. Blood 124 : Abstract 799, 2014.
P.565 掲載の参考文献
3) Sheibani K, et al : Monocytoid B-cell lymphoma, A novel B-cell neoplasm. Am J Pathol 124 : 310-318, 1986.
5) Harris NL, et al : A revised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Study Group. Blood 84 : 1361」392, 1994.
8) Nathwani BN, et al : Marginal zone B-cell lymphoma : a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 7 : 2486-2492, 1999.
10) Dierlamm J, et al : The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t (11 ; 18) (q21 ; q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93 : 3601-3609, 1999.
13) Tsai HK, et al : Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma. Ann Oncol 18 : 672-678, 2007.
P.570 掲載の参考文献
1) Leoncini L, et al : Burkitt lymphoma. In : World Health Organization Classification of Tumours. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p 262-264, International Agency for Research on Cancer, Lyon, 2008.
9) Peniket AI, et al : An EBMT registry matched study of allogeneic stem cell transplants for lymphoma : allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31 : 667-678, 2003.
11) Wossmann W, et al : Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 82 : 160-165, 2003.
P.575 掲載の参考文献
1) 田村和夫ほか : 老年期腫瘍学Geriatric Oncology, p 28-92, 文光堂, 2008.
2) The Non-Hodgkin's Lymphoma Classification Project : Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin s Lymphoma Classification Project. Ann Oncol 8 : 973-978, 1997,
P.580 掲載の参考文献
2) Mauz-Korholz C, et al : Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma : the GPOH-HD-2002 study. J Clin Oncol 28 (23) : 3680-3686, 2010.
4) 古賀友紀ほか : 本邦における小児Hodgkinリンパ腫157例の後方視的検討-小児がん研究4グループによる調査. 臨床血液 53 (4) : 443 -449, 2012.
6) Cairo MS, et al : Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≧15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma : results of the FAB LMB 96 study. J Clin Oncol 30 (4) : 387-393, 2012.
11) Sunami S, et al : 0utcome of 136 Children with Advanced Lymphoblastic Lymphoma Receiving an BFM -Type Therapy with Intensified Maintenance : A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study. Blood (56th ASH Annual Meeting Abstracts), 2014.
16) 森鉄也ほか : 小児未分化大細胞型リンパ腫に対するランダム化国際臨床試験ALCL99-R1国内登録例の解析. 臨床血液 55 (5) : 526-533, 2014.
X 節外リンパ腫の臓器別特徴と治療
P.595 掲載の参考文献
1) The Committee of Brain Tumor Registry of Japan. Report of Brain Tumor Registry of Japan (2001-2004), 13th ed. Neurol Med Chir (Tokyo) 54 (Suppl) : 1-102, 2014.
2) Deckert M, Paulus W : Malignant lymphoma. World Health Organization Histological Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 188-192, IARC, Lyon, 2007.
17) Ferreri AJ, et al ; International Extranodal Lymphoma Study Group (IELSG) : High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma : a randomised phase 2 trial. Lancet 374 : 1512-1520, 2009.
34) Omuro AMP, et al : Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the erderly : an Anocef and Goelams Intergroup study. J Clin Oncol 31 (Suppl) : abstr 2032, 2013.
36) Mishima K : Treatment of recurrent primary central nerve system lymphoma. Gan To Kagaku Ryoho 39 : 898-905, 2012.
P.601 掲載の参考文献
2) Isaacson P. Norton A : Extranodal lymphoma in miscellaneous sites. In : Extranodal Lymphomas (ed by Isaacson P, Norton A), p 289-298, Churchill Livingstone, New York, 1994.
3) Fletcher C, et al : Pathology and Genetics of Tumours of Soft Tissue and Bone : World Health Organization Classification of Tumours, p 306-308, International Agency for Research on Cancer, Lyon, 2002.
5) Zinzani PL, et al : Primary bolle lymphoma : experience with 52 patients. Haematologica 88 : 280-285, 2003.
11) Bacci G, et al : Primary non-Hodgkin's lymphoma of bone : results in 15 patients treated by radiotherapy combined with systemic chemotherapy. Cancer Treat Rep 66 : 1859- 1862, 1982.
17) Fletcher CDM, et al : World Health Organization classification of tumours of soft tissue and bone, 4th ed, IARC Press, Lyon, 2013.
P.607 掲載の参考文献
5) 菅谷誠ほか : 皮膚リンパ腫診療ガイドライン2011年改訂版. 日皮会誌 122 : 1513-1531, 2012.
P.612 掲載の参考文献
1) Said J, Cesarman E : Primary effusion lymphoma. In : World Health Organization Classification of tumors of haematopoietic and lymphoid tissues, p 260-261, International Agency for Research on Cancer (IARC), Lyon, 2008.
5) Nador RG, et al : Primary effusion lymphoma : a distinct clinic-pathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 88 : 645-656, 1996.
6) 清水郁夫ほか : AIDSとB型肝硬変に合併した原発性滲出性リンパ腫. 信州医学雑誌 54 : 131-136, 2006.
8) 四本美保子, 北野喜良 : 原発性滲出性リンパ腫. 日エイズ会誌 11 : 192-198, 2009.
9) 片野晴隆 : HHV-8関連リンパ増殖性疾患の病理組織学的診断. AIDSに合併するカポジ肉腫等のHHV-8関連疾患における診断と治療の手引き 第2版 (研究代表者片野晴隆), p 41-43, 平成25年度 厚生労働科学研究 エイズ対策研究事業「エイズ患者におけるカポジ肉腫関連ヘルペスウイルスが原因となる疾患の発症機構の解明と予防および治療法に関する研究」班, 平成25年度.
12) 味澤篤ほか : HIV関連悪性リンパ腫治療の手引きVer 2.0. 日エイズ会誌 15 : 46-57, 2013.
18) Hocquelox L, et al : Long-term remission of an AIDS-related primary effUsion lymphoma with antiviral therapy. AIDS 15 : 280-282, 2001.
P.618 掲載の参考文献
2) Sefanovic A, Lossos IS : Extranodal marginal zone lymphoma of the ocular adnexa. Blood 114 : 501-510, 2009.
6) Japanese study group of IgG4-related ophthalmic disease : A prevalence study of IgG4-related ophthalmic disease in Japan. Jpn J Ophthalmol 57 : 573-579, 2013.
9) Kase S, et al : IgG4-related inflammation of the orbit simulating malignant lymphoma. Anticancer Res 33 : 2779-2783, 2013.
P.622 掲載の参考文献
3) Lee GW, et al : Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy : a study by the Consortium for Improving Survival of Lymphoma. Leuk Lymphoma 56 : 1020-1026, 2015.
5) Mian M, et al : Early-stage diffuse large B cell lymphoma of the head and neck : clinico-biological haracterization and 18 year follow-up of 488 patients (IELSG 23 study). Ann Hematol 93 : 221-231, 2014.
9) Pfreundschuh M, et al : CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma : 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12 : 1013-1022, 2011.
10) 日本血液学会 (編) : 造血器腫瘍診療ガイドライン2013年版, 金原出版, 2013.
P.626 掲載の参考文献
1) Mian M, et al : High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma : an Internatinal Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. Leuk Lymphoma 52 : 823-832, 2011.
P.630 掲載の参考文献
1) Harris NL : Lymphoid proliferation of the salivary glands. Am J Clin Pathol 111 (Suppl 1) : 94-103, 1999.
2) Isaacson PG : Extranodal lymphomas : the MALT concept. Verh Dtsch Ges Pathol 76 : 14-23, 1992.
12) Ekstr6m Smedby K, et al : Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes : a pooled analysis within the InterLymph Consortium. Blood 111 : 4029-4038, 2008.
13) Jordan RCK, et al : High prevalence of B-cell monoclonality in labial gland biopsies of Japanese Sjogren's syndrome patients. Int J Hematol 64 : 47-52, 1996.
14) Bahler DW, et al : Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood 89 : 3335-3344, 1997.
P.636 掲載の参考文献
3) Jeanneret-Sozzi W, et al : Primary breast lymphoma : patient profile, outcome and prognostic factors. A multicentre Rare Cacer Network study. BMC Cancer 8 : 86, 2008.
9) Yoshida S, et al : Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol 18 : 398-405, 2005.
P.643 掲載の参考文献
5) Isaacson PG, et al : Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In : Tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours, Pathology, and Genetics (ed by Swerdlow SH, et al), p 214-217, IARC Press, Lyon, 2008.
6) Okabe M, et al : API2-MALT1 fusion defined a distinctive clinicopathologic subtype in pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Am J pathol 162 : 1113-1122, 2013.
7) Du MQ : MALT lymphoma : many roads lead to nuclear factor-κb activation. Histopathology 58 : 26-38, 2011.
10) Pittaluga S, et al : Lymphomatoid granulomatosis. In : Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, Pathology, and Genetics (ed by Swerdlow SH, et al), p 247-249, IARC Press, Lyon, 2008.
16) Chan JKC, et al : DLBCL associated with chronic in且ammation. In : Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, Pathology, and Genetics (ed by Swerdlow SH, et al), p 245-246, IARC Press, Lyon, 2008.
P.648 掲載の参考文献
1) Swerdlow SH, et al : Hepatosplenic T-cell lymphoma. In : World Health Organization Classification of Hematopoietic and Lymphoid Tissues, 4th ed, p 292-293, IARC Press, Lyon, 2008.
6) Ferreiro J, et al : Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma. PLoS One 91 e102977, 2014.
9) Nicolae A, et al : Frequent STAT5B mutations inγδhepatosplenic T-cell lymphomas. Leukemia 28 : 2244-2248, 2014.
19) Visnyei K, et al : HepatosplenicγδT-cell lymphoma : an overview. Clin Lymphoma Myeloma Leuk 13 : 360-369, 2013.
P.653 掲載の参考文献
2) Wotherspoon AC, et al : Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338 : 1175-1176, 1991.
5) Copie-Bergman C, et al : Proposal for a new histological grading system for posttreatment evaluation of gastric MALT lymphoma. Gut 52 : 1656, 2003.
6) Du MQ : MALT lymphoma ; many roads lead to nuclear factor-κb activation. Histopathology 58 : 26-38, 2011.
10) Tari A, et al : Predictive value of endoscopy and endoscopic ultrasonography for regression of gastric diffuse large B-cell lymphomas after Helicobacter pylori eradication. Dig Endoscopy 21 : 219-227, 2009.
14) Tan SY, et al : Type II EATL (epitheliotropic intestinal T-cell lymphoma) : a neoplasm of intraepithelial T-cells with predominant CD8αα phenotype. Leukemia 27 : 1688-1696, 2013.
P.658 掲載の参考文献
5) Ohsawa M, et al : Malignant lymphoma of the adrenal gland : its possible correlation with Epstein-Barr virus. Mod Pathol 9 : 534-543, 1996.
P.661 掲載の参考文献
5) Mazloom A, et al : Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment : the M. D. Anderson Cancer Center experience. Leuk Lymphoma 51 : 1217-1224, 2012.
P.665 掲載の参考文献
1) Ferry JA, Young RH : Malignant lymphoma, pseudolymphoma, and hematopoietic disorders of the female genital tract. Pathol Annu 26 : 227-263, 1991.
4) 岡本昌隆 : 悪性リンパ腫の病型頻度.悪性リンパ腫 臨床と病理-WHO分類 (第4版) に基づいて- (吉野正ほか編), p74-81, 先端医学社, 2009.
5) Isaacson PG, Norton AJ : Malignant lymphoma of the urogenital tract. In : Extranodal lymphomas. p273-287, Churchill Livingstone, Edinburgh, London, Madrid, Melbourne, New York, Tokyo, 1994.
9) Osborn BM, Robboy SJ : Lymphomas or leukemia presenting as ovarian tumors. An analysis of 42 cases. Cancer 52 : 1933-1943, 1983.
11) Chorlton I, et al : Primary malignant reticuloendotherial disease involving the vagina cervix and corpus uteri. Obstet Gynecol 44 : 735-748, 1974.
12) Khoury GG, Robinson A : Lymphoma of uterine cervix. Eur J Surg Oncol 15 : 65-67, 1989.
13) Jaffe ES (ed) : Surgical Pathology of the Lymph Nodes and Related Organs (Major Problems in Pathology), WB. Saunders, Philadelphia, 1985.
XI 特論
P.673 掲載の参考文献
2) Ioachim HL, Medeiros LJ : Ioachim'sLymph Node Pathology, 4th ed, p 227-237, Lippincott, Williams & Wilkins, Philadelphia, 2009.
4) O'Malley DP, Grimm KT : Atypical lymphoproliferative disorders. In : Knowel's Neoplastic Hematopathology, 3rd ed (ed by Orazi A, et al), p 340-353, Wolters Kluwer Health, Lippincott Williams & Wilkins, Baltimore, 2014.
5) 森茂郎ほか : 著しい多クローン性高γグロブリン血症と全身リンパ節の高度の形質細胞増殖を呈する症候群 : 形質細胞型Castlemanリンパ腫との異同. 日本網内系学会誌 20 : (補) 85-94, 1980.
7) Frizzera G : Atypical lymphoproliferative disorders. In : Neoplastic Hematopathology, 2nd ed (ed by Knowles DM), p 569-622, Lippincott Williams & Wilkins, Baltimore, 2001.
8) Kojima M, et al : Histopathological features of plasma cell dyscrasia with polyneuropathy and endocrine disturbances with special reference to germinal center lesions. Jpn J Clin Oncol 13 : 557-575, 1983.
P.678 掲載の参考文献
1) 高井和江ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 (5) : 320-325, 2010.
7) Frizzera G : Castleman's disease and related disorders. Semin Diagn Pathol 5 : 346-364, 1988.
P.682 掲載の参考文献
P.690 掲載の参考文献
10) Hummel M, et al : A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354 (23) : 2419-2430, 2006.
13) Gebauer N, et al : ID3 mutations are recurrent events in double-hit B-cell lymphomas. Anticancer Res 33 (11) : 4771-4778, 2013.
15) Gebauer N, et al : TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations. Leuk Lymphoma 56 (1) : 179-185, 2015.
26) Friedberg JW, et al : Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B-and T-cell non-Hodgkin lymphomas. J Clin Oncol 32 (1) : 44-50, 2014.
P.695 掲載の参考文献
1) Couzin-Frankel J : Breakthrough of the year 2013, Cancer immunotherapy. Science 342 : 1432-1433, 2013.
9) Davila ML, et al : Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6 : 224ra225, 2014.
11) Lee DW, et al : Tcells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults : a phase 1 dose-escalation trial. Lancet 385 : 517-528, 2015.
15) Brentjens RJ, et al : CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5 : 177ra138, 2013.
最近チェックした商品履歴
Loading...